These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 10372696)

  • 1. Final height after long-term treatment with triptorelin slow release for central precocious puberty: importance of statural growth after interruption of treatment. French study group of Decapeptyl in Precocious Puberty.
    Carel JC; Roger M; Ispas S; Tondu F; Lahlou N; Blumberg J; Chaussain JL
    J Clin Endocrinol Metab; 1999 Jun; 84(6):1973-8. PubMed ID: 10372696
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gonadotropin releasing hormone agonist treatment for central precocious puberty.
    Carel JC; Chaussain JL
    Horm Res; 1999; 51 Suppl 3():64-9. PubMed ID: 10592446
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of the factors affecting auxological response to GnRH agonist treatment and final height outcome in girls with idiopathic central precocious puberty.
    Arrigo T; Cisternino M; Galluzzi F; Bertelloni S; Pasquino AM; Antoniazzi F; Borrelli P; Crisafulli G; Wasniewska M; De Luca F
    Eur J Endocrinol; 1999 Aug; 141(2):140-4. PubMed ID: 10427157
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term outcome after depot gonadotropin-releasing hormone agonist treatment of central precocious puberty: final height, body proportions, body composition, bone mineral density, and reproductive function.
    Heger S; Partsch CJ; Sippell WG
    J Clin Endocrinol Metab; 1999 Dec; 84(12):4583-90. PubMed ID: 10599723
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum insulin-like growth factor I (IGF-I) and IGF-binding protein 3 levels are increased in central precocious puberty: effects of two different treatment regimens with gonadotropin-releasing hormone agonists, without or in combination with an antiandrogen (cyproterone acetate).
    Juul A; Scheike T; Nielsen CT; Krabbe S; Müller J; Skakkebaek NE
    J Clin Endocrinol Metab; 1995 Oct; 80(10):3059-67. PubMed ID: 7559897
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of central precocious puberty: lessons from a 15 years prospective trial. German Decapeptyl Study Group.
    Partsch CJ; Heger S; Sippell WG
    J Pediatr Endocrinol Metab; 2000 Jul; 13 Suppl 1():747-58. PubMed ID: 10969917
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-acting GnRH analogue triptorelin therapy in central isosexual precocious puberty.
    Bajpai A; Sharma J; Kabra M; Gupta AK; Menon PS
    Indian Pediatr; 2002 Jul; 39(7):633-9. PubMed ID: 12147888
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of complete and incomplete suppression of pituitary-gonadal activity in girls with central precocious puberty: influence on growth and predicted final height. The German-Dutch Precocious Puberty Study Group.
    Partsch CJ; Hümmelink R; Peter M; Sippell WG; Oostdijk W; Odink RJ; Drop SL
    Horm Res; 1993; 39(3-4):111-7. PubMed ID: 8262471
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Growth, bone maturation and height prediction after three years of therapy with the slow release GnRH-agonist Decapeptyl-Depot in children with central precocious puberty.
    Hümmelink R; Oostdijk W; Partsch CJ; Odink RJ; Drop SL; Sippell WG
    Horm Metab Res; 1992 Mar; 24(3):122-6. PubMed ID: 1533604
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Final height of girls with central precocious puberty, untreated versus treated with cyproterone acetate or GnRH analogue. A comparative study with re-evaluation of predictions by the Bayley-Pinneau method.
    Kauli R; Galatzer A; Kornreich L; Lazar L; Pertzelan A; Laron Z
    Horm Res; 1997; 47(2):54-61. PubMed ID: 9030968
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sexual precocity in boys: accelerated versus slowly progressive puberty gonadotropin-suppressive therapy and final height.
    Lazar L; Pertzelan A; Weintrob N; Phillip M; Kauli R
    J Clin Endocrinol Metab; 2001 Sep; 86(9):4127-32. PubMed ID: 11549638
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Comparison between complete and incomplete suppression of the hypophyseal-gonadal axis in girls with central precocious puberty: effect on growth and prospective final height].
    Partsch CJ; Hümmelink R; Sippell WG; Oostdijk W; Odink RJ; Drop SL
    Monatsschr Kinderheilkd; 1993 Dec; 141(12):935-9. PubMed ID: 8114776
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Long-term experiences with a long-acting gonadotropin releasing hormone analog in therapy of central precocious puberty: effect on body growth].
    Hofmann-Ehrhart B; Schulz U; Kluge M; Wandl-Vergesslich K; Waldhauser F
    Wien Klin Wochenschr; 1995; 107(14):413-7. PubMed ID: 7668000
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term results with a slow-release gonadotrophin-releasing hormone agonist in central precocious puberty. Dutch-German Precocious Puberty Study Group.
    Oostdijk W; Drop SL; Odink RJ; Hümmelink R; Partsch CJ; Sippell WG
    Acta Paediatr Scand Suppl; 1991; 372():39-45; discussion 46. PubMed ID: 1833950
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Growth, development and prediction of body height in children with central precocious puberty after 3 years of therapy with Decapeptyl-Depot, a slow-releasing GnRH agonist].
    Hümmelink R; Oostdijk W; Partsch CJ; Odink RJ; Drop SL; Sippell WG
    Cesk Pediatr; 1994; 49(1):7-12. PubMed ID: 8124755
    [TBL] [Abstract][Full Text] [Related]  

  • 16. End results in central precocious puberty with GnRH analog treatment: the data of the Italian Study Group for Physiopathology of Puberty.
    Antoniazzi F; Arrigo T; Cisternino M; Galluzzi F; Bertelloni S; Pasquino AM; Borrelli P; Osio D; Mengarda F; De Luca F; Tatò L
    J Pediatr Endocrinol Metab; 2000 Jul; 13 Suppl 1():773-80. PubMed ID: 10969920
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of central precocious puberty and gonadotropin-releasing hormone analogue treatment on peak bone mass and final height in females.
    Bertelloni S; Baroncelli GI; Sorrentino MC; Perri G; Saggese G
    Eur J Pediatr; 1998 May; 157(5):363-7. PubMed ID: 9625331
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adult height in girls with central precocious puberty treated with gonadotropin-releasing hormone analogues and growth hormone.
    Pasquino AM; Pucarelli I; Segni M; Matrunola M; Cerroni F
    J Clin Endocrinol Metab; 1999 Feb; 84(2):449-52. PubMed ID: 10022399
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased final height in precocious puberty after long-term treatment with LHRH agonists: the National Institutes of Health experience.
    Klein KO; Barnes KM; Jones JV; Feuillan PP; Cutler GB
    J Clin Endocrinol Metab; 2001 Oct; 86(10):4711-6. PubMed ID: 11600530
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adult height in girls with idiopathic true precocious puberty.
    Brauner R; Adan L; Malandry F; Zantleifer D
    J Clin Endocrinol Metab; 1994 Aug; 79(2):415-20. PubMed ID: 8045957
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.